New York State Common Retirement Fund Purchases 6,599 Shares of AxoGen, Inc. (AXGN)
New York State Common Retirement Fund lifted its position in shares of AxoGen, Inc. (NASDAQ:AXGN) by 26.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,400 shares of the medical equipment provider’s stock after buying an additional 6,599 shares during the period. New York State Common Retirement Fund owned about 0.09% of AxoGen worth $526,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Thompson Davis & CO. Inc. boosted its position in shares of AxoGen by 575.0% during the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 5,750 shares during the period. Bank of America Corp DE boosted its position in AxoGen by 8.7% during the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares during the last quarter. Parametric Portfolio Associates LLC boosted its position in AxoGen by 0.9% during the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in AxoGen during the second quarter valued at approximately $201,000. Finally, Nationwide Fund Advisors boosted its position in AxoGen by 5.5% during the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares during the last quarter. 67.44% of the stock is owned by institutional investors.
Several research analysts recently commented on AXGN shares. BidaskClub cut AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Roth Capital reaffirmed a “buy” rating and issued a $21.00 price objective (up from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. Leerink Swann began coverage on AxoGen in a research report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $18.00 price objective on shares of AxoGen in a research report on Monday, August 21st. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.
AxoGen, Inc. (AXGN) opened at $25.05 on Monday. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. AxoGen, Inc. has a 52 week low of $8.00 and a 52 week high of $25.15.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.06). The company had revenue of $16.05 million for the quarter, compared to analyst estimates of $15.55 million. AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The company’s revenue for the quarter was up 43.2% on a year-over-year basis. research analysts anticipate that AxoGen, Inc. will post -0.31 earnings per share for the current year.
In other news, Director Robert James Rudelius sold 16,143 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total transaction of $290,574.00. Following the transaction, the director now owns 43,273 shares in the company, valued at $778,914. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.33% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Purchases 6,599 Shares of AxoGen, Inc. (AXGN)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/11/13/new-york-state-common-retirement-fund-purchases-6599-shares-of-axogen-inc-axgn.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.